| 耿一凡,吴 萌,江 波,韩正祥,杜秀平.PIV、NLR、PLR、MLR对晚期非小细胞肺癌免疫治疗近期疗效和预后的评估价值[J].,2023,(1):163-167 |
| PIV、NLR、PLR、MLR对晚期非小细胞肺癌免疫治疗近期疗效和预后的评估价值 |
| Evaluation Value of PIV, NLR, PLR and MLR in the Short-Term Efficacy and Prognosis of Immunotherapy for Advanced Non-Small Cell Lung Cancer |
| 投稿时间：2022-04-07 修订日期：2022-04-28 |
| DOI：10.13241/j.cnki.pmb.2023.01.032 |
| 中文关键词: 晚期 非小细胞肺癌 免疫治疗 疗效 预后 PIV NLR PLR MLR |
| 英文关键词: Advanced Non-small cell lung cancer Immunotherapy Efficacy Prognosis PIV NLR PLR MLR |
| 基金项目:江苏省2020年高层次人才"六个一工程"拔尖人才科研项目(LGT2020006) |
|
| 摘要点击次数: 793 |
| 全文下载次数: 561 |
| 中文摘要: |
| 摘要 目的：评价泛免疫炎症值（PIV）、中性粒细胞与淋巴细胞的比值（NLR）、血小板与淋巴细胞的比值（PLR）、单核细胞与淋巴细胞的比值（MLR）对接受程序性细胞死亡受体-1（PD-1）抑制剂治疗的晚期非小细胞肺癌（NSCLC）患者近期疗效和预后的评估价值。方法：收集徐州医科大学附属医院2018年1月至2020年1月使用PD-1抑制剂治疗的132例晚期NSCLC患者的临床资料，根据免疫治疗前的PIV、NLR、PLR、MLR最佳阈值分组，分析其与疾病控制率（DCR）的关系。采用Kaplan-Meier法绘制生存曲线，通过COX回归分析确定影响生存预后的危险因素。结果：PIV、NLR、PLR、MLR最佳阈值分别为286.17、3.07、250.97、0.33。NLR≤3.07的患者DCR更高（P＜0.05）。PIV≤286.17组、NLR≤3.07组、PLR≤250.97组和MLR≤0.33组患者的中位总生存期（OS）更长。COX回归分析结果显示： PIV、NLR、PLR、MLR是影响患者预后的危险因素（P＜0.05）。结论：NLR≤3.07的患者近期疗效更好，PIV、NLR、PLR、MLR低水平的患者预后更佳，检测PIV、NLR、PLR、MLR对晚期NSCLC患者的近期疗效和预后评估具有一定的指导意义。 |
| 英文摘要: |
| ABSTRACT Objective: To evaluate the short-term efficacy of pan-immune-inflammatory value (PIV), neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), monocyte-to-lymphocyte ratio (MLR) in patients with advanced non-small cell lung cancer (NSCLC) who were treated with programmed cell death-1 (PD-1) inhibitors and the evaluation value of prognosis. Methods: The clinical data of 132 patients with advanced NSCLC who were treated with PD-1 inhibitors in the Affiliated Hospital of Xuzhou Medical University from January 2018 to January 2020 were collected. According to the optimal threshold grouping of PIV, NLR, PLR and MLR before immunotherapy, the relationship between them and disease control rate (DCR) was analyzed. Kaplan-Meier method was used to draw the survival curve, and Cox regression analysis was used to determine the risk factors affecting survival and prognosis. Results: The optimal thresholds of PIV, NLR, PLR and MLR were 286.17, 3.07, 250.97 and 0.33 respectively. Patients with NLR ≤3.07 had higher DCR (P＜0.05). The median overall survival (OS) were longer in PIV ≤286.17 group, NLR ≤3.07 group, PLR ≤250.97 group and MLR ≤0.33 group. Cox regression analysis showed that PIV, NLR, PLR and MLR were the risk factors affecting the prognosis of patients (P＜0.05). Conclusion: Patients with NLR ≤3.07 have better short-term efficacy, and patients with low levels of PIV, NLR, PLR and MLR have better prognosis. Detection of PIV, NLR, PLR and MLR has certain guiding significance for the short-term efficacy and prognosis evaluation of patients with advanced NSCLC. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
